Efficacy of 3 years of adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance

doi:10.4254/wjh.v4.i12.389

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 12

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1994)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-3) series.

Item

Count

PDF

250

HTML

1610

Tables (1-3)

134

Sum=1994

Dec 27, 2012 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Hepatol. Dec 27, 2012; 4(12): 389-393
Published online Dec 27, 2012. doi: 10.4254/wjh.v4.i12.389

Table 2 Control of the therapeutic effect in the two groups

Group	Baseline	n	12 wk		24 wk		52 wk		104 wk		156 wk
Group	(copies/mL)	n	VR¹	BR²	VR¹	BR²	VR¹	BR²	VR¹	BR²	VR¹	BR²
A	10³-10⁵	18	16 (88.8)¹	16 (88.8)	16 (88.8)¹	16 (88.8)	16 (88.8)³	16 (88.8)	16 (88.8)¹	16 (88.8)	16 (88.8)¹	16 (88.8)
A	≥ 10⁶	34	14 (41.1)	24 (70.5)	15 (44.1)	30 (88.2)	16 (47.0)	22 (64.7)	16 (47.0)	26 (76.4)	16 (47.0)	18 (52.9)
B	10³-10⁵	11	9 (81.8)⁴	9 (81.8)	9 (81.8)⁴	10 (90.9)	9 (81.8)⁴	10 (90.9)	8 (72.7)	9 (81.8)	9 (81.8)⁴	9 (81.8)
B	≥ 10⁶	13	6 (46.1)	10 (76.9)	6 (46.1)	10 (76.9)	6 (46.1)	9 (69.2)	7 (53.8)	9 (69.2)	6 (46.1)	9 (69.2)

A	HBeAg positive	36	18 (50.0)	26 (72.2)	20 (55.5)	30 (83.3)	20 (55.5)	26 (72.2)	22 (61.1)	26 (72.2)	20 (55.5)	22 (61.1)
A	HBeAg negative	16	12 (75.0)	14 (87.5)	14 (87.5)	16 (100.0)	12 (75.0)	12 (75.0)	14 (87.5)	16 (100.0)	12 (75.0)	6 (75.0)
B	HBeAg positive	17	8 (47.8)	12 (70.5)	9 (52.9)	15 (88.2)	9 (52.9)	15 (88.2)	9 (52.9)	13 (76.4 )	10 (58.8)	11 (64.7)
B	HBeAg negative	7	5 (71.4)	6 (85.7)	5 (71.4)	6 (85.7)	6 (85.7)	6 (85.7)	5 (71.4)	6 (85.7)	5 (71.4)	6 (85.7)

A	ALT < 2 × ULN	20	17 (85.0)	18 (90.0)	16 (80.0)	18 (90.0)	14 (70.0)	14 (70.0)	14 (70.0)	18 (90.0)	14 (70.0)	14 (70.0)
A	ALT > 2 × ULN	32	18 (56.2)	22 (68.7)	18 (56.2)	28 (87.5)	18 (56.2)	26 (81.2)	22 (68.7)	24 (75.0)	18 (56.25)	20 (62.5)
B	ALT < 2 × ULN	10	8 (80.00)	9 (90.0)	8 (80.0)	10 (100.0)	8 (80.0)	10 (100.0)	8 (80.0)	10 (100.0)	8 (80.0)	9 (90.0)
B	ALT > 2 × ULN	14	8 (57.1)	10 (71.4)	8 (57.1)	12 (85.7)	10 (71.4)	12 (85.7)	10 (71.4)	12 (85.7)	10 ( (71.4)	12 (85.7)

Group A: Treated with adefovir; Group B: Treated with adefovir and lamivudine;

¹VR: Defined as HBV DNA < lower detection limit;

²BR: Defined as ALT < lower detection limit;

³P < 0.01 (χ² = 4.35-5.4) vs group A with baseline HBV DNA ≥ 10⁶ copies/mL;

⁴P < 0.05 (χ² = 4.1-5.0) vs group B with baseline HBV DNA ≥ 10⁶ copies/mL. VR: Virological response; BR: Biochemical response; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; ALT: Alanine aminotransferase.

Citation: Song MN, Hong MZ, Luo DQ, Huang WQ, Min F, Fan RH, Wu WB, Zhang L. Efficacy of 3 years of adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance. World J Hepatol 2012; 4(12): 389-393
URL: https://www.wjgnet.com/1948-5182/full/v4/i12/389.htm
DOI: https://dx.doi.org/10.4254/wjh.v4.i12.389